Head and Neck Neuroendocrine Carcinoma
Head and neck neuroendocrine carcinomas most frequently harbor alterations in TP53, RB1, KMT2D, HRAS, and SMARCA4 .
TP53 Mutation, KMT2D Mutation, RB1 Nonsense, RB1 Mutation, and HRAS Mutation are the most common alterations in head and neck neuroendocrine carcinoma .
There is 1 clinical trial for head and neck neuroendocrine carcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains head and neck neuroendocrine carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
Abemaciclib and nivolumab are the most common interventions in head and neck neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.